Simple Summary Over the past decade, cell-based immunotherapy has become a powerful
strategy in solid cancer therapy. Tumor-infiltrating lymphocytes (TILs) are a group of …

Dendritic cell (DC) vaccination in cancer patients aims to induce or augment an effective
antitumor immune response against tumor antigens and was first explored in a clinical trial …

We performed an extensive immunogenomic analysis of more than 10,000 tumors
comprising 33 diverse cancer types by utilizing data compiled by TCGA. Across cancer …

Combinations of BRAF inhibitors and MEK inhibitors (BRAFi+ MEKi) are FDA-approved to
treat BRAF V600E/K-mutant melanoma. Efficacy of BRAFi+ MEKi associates with cancer cell …

Resistance to cancer therapy remains a major challenge in clinical oncology. Although the
initial treatment phase is often successful, eventual resistance, characterized by tumour …

Malignant melanoma, as a highly aggressive skin cancer, is strongly associated with
mutations in serine/threonine protein kinase B-RAF (BRAF, where RAF stands for rapidly …

Simple Summary Cutaneous melanoma represents the most aggressive form of skin cancer
and its occurrence, development, and progression are based on the accumulation of several …

With the success of immunotherapy in cancer, understanding the tumor immune
microenvironment (TIME) has become increasingly important; however in pediatric brain …

Several kinase inhibitors that target aberrant signaling pathways in tumor cells have been
deployed in cancer therapy. However, their impact on the tumor immune microenvironment …

RAS genes are the most frequently mutated oncogenes in cancer. These mutations occur in
roughly half of the patients with colorectal cancer (CRC). RAS mutant tumors are resistant to …